Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.04.024
- Author:
Di-Wen PANG
1
;
Fei-Li CHEN
1
;
Han-Guo GUO
1
;
Xin-Miao JIANG
1
;
Xiao-Juan WEI
1
;
Si-Chu LIU
1
;
Ling HUANG
1
;
Zhan-Li LIANG
1
;
Wen-Yu LI
2
Author Information
1. Department of Lymphoma Division, Guangdong Provincial People's Hospital, South China University of Technology, Guangzhou 510100, Guangdong Province, China.
2. Department of Lymphoma Division, Guangdong Provincial People's Hospital, South China University of Technology, Guangzhou 510100, Guangdong Province, China E-mail: lwy80411@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Central Nervous System;
Central Nervous System Neoplasms/drug therapy*;
Humans;
Lymphoma, Non-Hodgkin/drug therapy*;
Methotrexate/therapeutic use*;
Retrospective Studies;
Rituximab/therapeutic use*;
Temozolomide/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(4):1175-1180
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical efficacy of high dose methotrexate (HD-MTX), temozolomide (TMZ), and rituximab (R) in the treatment of patients with primary central nervous system lymphoma (PCNSL).
METHODS:Clinical data of patients with PCNSL diagnosed and treated in Guangdong Provincial People's Hospital from February 2010 to May 2017 were collected. First, patients were given 6-8 cycles of MTX (3.5 g/m
RESULTS:There were 42 patients enrolled in the study, 17 cases in HD-MTX+TMZ group and 25 cases in HD-MTX+TMZ+R group. The median PFS and OS times in HD-MTX+TMZ+R group were 56.7 months and N/A, respectively, while, 7.3 months and 34.7 months in HD-MTX+TMZ group, respectively. In addition, there was no significant difference in median survival between patients who received TMZ maintenance therapy and those who were only actively monitored. During the induction period, all the patients had grade 1-2 nausea and vomiting, while in the consolidation treatment period, no grade 3/4 toxicity was observed.
CONCLUSION:The combination of HD-MTX+TMZ+R in the treatment of PCNSL patients shows a definite short-term effect, which can increase the survival rate of the patients. The side effects are mild, and the patients can generally tolerate.
